← All Mesoblast LTD filings

Mesoblast LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
MESO
Mesoblast LTD
20-F: Mesoblast Secures Ryoncil FDA Approval, Boosts Capital
Mesoblast Limited achieved a significant milestone with FDA approval for Ryoncil, its first mesenchymal stromal cell therapy, and successfully raised $160 million in a private placement, despite ongoing operating losses.
NASDAQ
MESO
Mesoblast LTD
20-F: Mesoblast's FY24 Results: Focus on Regulatory Approval and Cost Management
Mesoblast reports its FY24 results, highlighting efforts to secure regulatory approval for remestemcel-L and manage operational costs.